Centogene N.V. Common Shares Stock Price, News & Analysis

Centogene N.V. (historically trading under the symbol CNTG) has described itself as the essential life science partner for data-driven answers in rare and neurodegenerative diseases. The company’s work has focused on providing what it calls data-driven, life-changing answers to patients, physicians, and pharmaceutical companies by integrating multiomic technologies with the CENTOGENE Biodatabank to support precision medicine.

According to company disclosures, CENTOGENE’s mission has been to enable rapid and reliable diagnosis for patients, support a more precise physician understanding of disease states, and accelerate and de-risk targeted drug discovery, development, and commercialization for pharma partners. The company reports that it has built a network of approximately 30,000 active physicians and operates ISO, CAP, and CLIA certified multiomic reference laboratories in Germany that utilize phenomic, genomic, transcriptomic, epigenomic, proteomic, and metabolomic datasets.

Since its founding in 2006, CENTOGENE states that it has captured data in the CENTOGENE Biodatabank, which it describes as a real-world integrated multiomic data repository in rare and neurodegenerative diseases. The company reports that this Biodatabank includes data from over 850,000 patients from more than 120 highly diverse countries, with over 70% of patients of non-European descent, and that these data have contributed to more than 300 peer-reviewed publications. CENTOGENE also highlights that it has supported over 50 collaborations with pharmaceutical partners.

Historically, CENTOGENE has described two main areas of activity: diagnostic testing for rare and neurodegenerative diseases and collaborations with pharmaceutical companies. In diagnostics, the company has referenced multiomic testing solutions and whole exome and whole genome sequencing-based offerings, as well as a portfolio referred to as MOx, which combines different data types to support diagnosis. In its pharma-related activities, CENTOGENE has pointed to collaborations in target and drug screening, clinical development, market access and expansion, and the provision of CENTOGENE Biodata Licenses and Insight Reports.

Public communications also describe CENTOGENE’s involvement in large-scale research initiatives, such as the Rostock International Parkinson's Disease (ROPAD) Study, a global epidemiological study focusing on the role of genetics in Parkinson’s disease. The company has reported that ROPAD is aimed at characterizing the genetics of Parkinson’s disease to improve understanding of disease etiology, diagnosis, and severity, and that tens of thousands of patients have been enrolled. In this context, CENTOGENE has highlighted findings on genetic risk factors, including variants in genes such as LRRK2, GBA1, and RAB32, and has emphasized the role of genetic testing in the emerging era of gene-targeted clinical trials.

In addition, CENTOGENE has described collaborations in lysosomal diseases and Gaucher disease, including work with partners such as Critical Path Institute and Evotec SE. The company has reported that its Biodatabank and translational biomarkers have been used alongside external platforms to identify and characterize potential therapeutic candidates, including a small molecule candidate for neuronopathic Gaucher disease.

A significant corporate development is that, as disclosed in a March 12, 2025 announcement, Centogene N.V. closed a transaction to sell its operating subsidiaries to an affiliate of Charme Capital Partners Limited. The company reported that it sold 100% ownership in Centogene GmbH, described as its sole operating subsidiary, along with certain intercompany receivables and the assumption of a loan. Following the closing of this transaction, Centogene N.V. stated that it and its remaining subsidiary, Centogene Switzerland AG, would no longer have any operations. The company further indicated that it intends to liquidate Centogene Switzerland AG and that Centogene N.V. will enter dissolution and liquidation in accordance with the laws of the Netherlands and its organizational documents, as resolved upon by shareholders at an Extraordinary General Meeting.

Centogene N.V. has communicated that it expects to make a liquidation distribution to its shareholders, with the exact amount and timing dependent on running costs, reserves, and the liquidation process. The company has also stated that its reporting obligations under the U.S. Securities Exchange Act have been suspended and that it expects its securities to cease to be quoted on the OTC market. Earlier, in connection with the strategic transaction, the company had announced that, following the closing, Centogene N.V. and its remaining subsidiaries would no longer have any operations and that it intended to enter into dissolution and liquidation.

Given these developments, CNTG represents a company that historically operated in the research and development and diagnostic testing space for rare and neurodegenerative diseases, with a strong emphasis on multiomic data integration and partnerships, but that has since sold its operating subsidiaries and initiated a process of dissolution and liquidation. For investors and researchers, CNTG is therefore primarily of historical interest, documenting the evolution of a data-driven rare disease and neurodegenerative disease platform and its subsequent corporate restructuring and wind-down.

Business focus and activities

Based on its public descriptions, CENTOGENE has focused on:

• Rare and neurodegenerative diseases: Providing diagnostic testing and data-driven insights in areas such as lysosomal diseases, Gaucher disease, Niemann-Pick type C, Parkinson’s disease, and other rare and neurodegenerative conditions.
• Multiomic technologies: Integrating phenomic, genomic, transcriptomic, epigenomic, proteomic, and metabolomic datasets in certified reference laboratories in Germany.
• Real-world data aggregation: Building and maintaining the CENTOGENE Biodatabank, which the company describes as containing data from hundreds of thousands of patients and contributing to hundreds of scientific publications.
• Pharma collaborations: Supporting pharmaceutical partners across drug discovery, development, and commercialization through collaborations, biodata licenses, and insight reports.
• Large-scale research programs: Leading or co-leading observational and epidemiological studies, including the ROPAD Study in Parkinson’s disease and projects in lysosomal diseases.

Corporate status

According to the company’s March 12, 2025 announcement, after the sale of its operating subsidiaries to an affiliate of Charme Capital Partners, Centogene N.V. and its remaining subsidiary will no longer have operations and the company intends to enter dissolution and liquidation. The company has also indicated that its reporting obligations under the U.S. Securities Exchange Act have been suspended and that it expects its securities to cease to be quoted on the OTC market. As a result, CNTG should be viewed as a former operating company undergoing liquidation rather than an ongoing operating business.

FAQs